ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Real-time Estimate Cboe BZX  -  01:47 2022-08-19 pm EDT
13.93 USD   -3.53%
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
PR
08/15ALX ONCOLOGY : Corporate Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization1 3 435870588--
Enterprise Value (EV)1 3 000507326249241
P/E ratio -31,2x-10,4x-4,95x-4,45x-4,26x
Yield -----
Capitalization / Revenue 2 906x---39,3x
EV / Revenue 2 538x---16,1x
EV / EBITDA -69,0x-6,07x-2,82x-1,71x-1,11x
Price to Book 7,99x2,40x2,28x2,18x3,81x
Nbr of stocks (in thousands) 39 84540 50040 747--
Reference price (USD) 86,221,514,414,414,4
Announcement Date 03/18/202102/28/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 4,801,18---15,0
EBITDA1 --43,5-83,5-116-146-218
Operating profit (EBIT)1 --43,7-83,6-121-154-199
Operating Margin --3 694%----1 328%
Pre-Tax Profit (EBT)1 --45,5-83,5-126-157-193
Net income1 --45,7-83,5-126-158-197
Net margin --3 870%----1 317%
EPS2 -1,15-2,76-2,07-2,92-3,25-3,39
Dividend per Share2 ------
Announcement Date 05/05/202003/18/202102/28/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 ------
EBITDA1 ----33,3-34,9-
Operating profit (EBIT)1 -28,5-24,7-33,8-33,5-36,0-37,0
Operating Margin ------
Pre-Tax Profit (EBT)1 -28,5-24,5-32,9-33,4-36,1-37,2
Net income1 -28,4-24,5-32,9-33,5-36,3-37,4
Net margin ------
EPS2 -0,70-0,60-0,81-0,81-0,85-0,86
Dividend per Share ------
Announcement Date 02/28/202205/09/202208/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 -434364262340347
Leverage (Debt / EBITDA) -9,99x4,36x2,26x2,33x1,59x
Free Cash Flow1 --38,3-68,8-91,5-157-201
ROE (Net Profit / Equities) --25,5%-21,1%-36,1%-48,0%-65,0%
Shareholders' equity1 -180396350329303
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 -10,88,946,356,623,79
Cash Flow per Share2 --2,07-1,69-2,52-2,12-2,05
Capex1 -0,030,672,002,705,00
Capex / Sales -2,62%---33,4%
Announcement Date 05/05/202003/18/202102/28/2022---
1 USD in Million
2 USD
Estimates
Key data
Capitalization (USD) 588 387 618
Number of employees 52
Free-Float 73,6%
Free-Float capitalization (USD) 433 196 101
Avg. Exchange 20 sessions (USD) 3 987 042
Average Daily Capital Traded 0,68%
EPS & Dividend